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Abstract
Background: The pandemic influenza A (H1N1) 2009 (H1N1pdm09) virus infection caused illness and death among
people worldwide, particularly in hematologic/oncologic patients because influenza infected individuals can shed
virus for prolonged periods, thus increasing the chances for the development of drug-resistant strains such as
oseltamivir-resistant (OST-r) variant.
Methods: The aim of our study was to retrospectively evaluate the clinical importance of OST-r variant in
circulating strains of the pandemic H1N1pdm09 virus. By means of RT-PCR and Sanger sequencing we analysed the
presence of OST-r variant in 76 H1N1pdm09 laboratory-confirmed cases, hospitalized at the hematologic/oncologic
ward at Spedali Civili of Brescia –Italy.
Results: Out of 76 hospitalized hematologic/oncologic patients, 23 patients (30.2%) were infected by H1N1pdm09
virus. Further investigation revealed that 3 patients were positive for the OST-r variant carrying the H275Y mutation.
All the 23 infected patients were immuno-compromised, and were under treatment or had been treated previously
with oseltamivir. Three patients died (13%) after admission to intensive care unit and only one of them developed
H275Y mutation.
Conclusions: Our retrospective observational study shows that pandemic influenza A (H1N1) 2009 virus can cause
significant morbidity and even mortality in hematologic/oncologic patients and confirms the high rate of
nosocomial transmission of pandemic H1N1pdm09 virus in these critical subjects. Indeed, the reduction in host
defences in these hospitalized patients favoured the prolonged use of antiviral therapy and permitted the
development of OST-r strain. Strategies as diagnostic vigilance, early isolation of patients and seasonal influenza A
(H1N1) vaccination may prevent transmission of influenza in high risk individuals.
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Background
The pandemic influenza A (H1N1) 2009 virus (H1N1-
pdm09) broke out in Mexico and USA during the late
spring and early summer of 2009. Due to its rapid wide-
spread transmission, H1N1pdm09 virus was declared as
novel influenza pandemic virus in June 2009 by the
World Health Organization (WHO) [1-6]. Indeed the
genomic analysis of this new 2009 influenza virus indi-
cated a genetic viral reassortment and it contained genes
of influenza A virus strains that are endemic in swine,
avian and human species [7,8].
The 2009 pandemic virus was found susceptible to
neuraminidase inhibitors (NAI) antiviral drugs such as
oseltamivir (Tamiflu TM) and zanamivir (Relenza TM)
that have been used extensively for chemoprophylaxis
and treatment in 2009 pandemic virus. The emergence
of oseltamivir-resistant (OST-r) pandemic H1N1pdm09
variant, characterized by the single amino acid change
H275Y in the neuraminidase (NA) glycoprotein [9-13],
was detected in many countries [14], especially in Italy
[15-18]. The OST-r variant has been detected in immuno-
compromised patients that are at risk for serious com-
plications from seasonal influenza [2,19-22]. The nosoco-
mial transmission of H1N1pdm09 resistant variants may
cause an increase of morbility and mortality in this group
of subjects.
The aim of this study was to investigate nosocomial
viral transmission of H1N1pdm09 in a cluster of critical
hematologic patients and the clinical importance and
impact of OST-r variant viruses.
Methods
Study population
In January 2011, an outbreak of H1N1pdm09 occurred in
a Hematology ward at Spedali Civili of Brescia (Italy). Re-
spiratory specimens from symptomatic contact patients of
the presumed index patient were analyzed by reverse
transcriptase-polymerase chain reaction (RT-PCR) for in-
fluenza A/B virus. Screening was performed on 134 speci-
mens obtained from 76 hospitalized patients (age range:
23-76 years). H1N1pdm09 positive samples were further
tested for OST-r variant.
In our laboratory, the current diagnostic algorithm for
testing of Influenza includes primary screening using a
multiplex commercial real-time RT-PCR assay (Flu A/
Flu B Q-PCR Alert Kit, Nanogen Advanced Diagnostics,
Italy) targeting the matrix gene of all human influenza A
and B viruses. Positive samples were subsequently tested
for H1N1pdm09 sub-type by a commercial assay (Fast
set H1N1v-Arrowdiagnostics, Italy). H1N1pdm09 posi-
tive samples were further tested for oseltamivir resis-
tance using an in house RT-PCR [23,24] and the results
confirmed using Sanger sequencing method. We retro-
spectively obtained the clinical data of the confirmed
cases and reviewed the medical records. All patients
submitted to RT-PCR test for H1N1pdm09 presented
influenza-like illness (ILI) symptoms, and the positive cases
were administered oseltamivir therapy: 75 mg twice/ day,
for five days.
Clinical samples (nasopharyngeal swabs, bronchoalve-
olar washings or respiratory secretions) were collected
from all patients using a pernasal flocked swab and
stored in a UTM-RT tube (Kit Cat. No. 360c, Copan
Italia, Brescia, Italy). Each sample was immediatly tested
by real-time PCR in order to identify A and B influenza
viruses as previously described. Diagnosis of influenza
was invariably provided within 8–24 hours after the re-
ceipt of the sample.
Ethical considerations
The investigation of this outbreak did not involve any
planned activity that could have been reviewed prospec-
tively by an institutional review board or ethics commit-
tee. The Ethics commette was consulted retrospectively
and agreed to the approach as described for reporting
clinical information obtained during the investigation.
All patients received study information and signed in-
formed consent.
RNA extraction, real-time RT-PCR , multiplex and one step
RT-PCR
DNA/RNA was extracted by an automatic nucleic acid
platform (Nuclisens EasyMag - Biomerieux). Aliquots of
400 μl of each respiratory sample were added to 1600 μl
of lysis buffer and the mix was loaded in the instrument.
After a lysis step (10 minutes at room temperature), 65 μl
of magnetic silica, 10 μl of internal control (CPE, Nanogen
Advanced Diagnostics S.R.L), purified beta globin sequence
and 55 μl of wash reagent were added to each specimen.
Total nucleic acid was automatically extracted, eluted in
110 μl of specific buffer and immediately processed by real
time PCR. Aliquots were stored at -80°C.
Extracted viral RNA was tested by Flu A/Flu B Q-PCR
Alert Kit (Nanogen Advanced Diagnostics, Italy), using
ABI Prism 7300 Fast Real Time PCR System (Applied
Biosystems, Italy). This test is based on simultaneous
amplification of the matrix region of Influenza A and B
and of the internal control human beta globin gene. Beta
globin DNA was added to each sample to monitor the
efficiency of extraction and amplification procedures.
Specific TaqMan probes labelled with different reporter
molecules were used to detect amplification of the
targets.
The positive samples for influenza A virus were tested
for H1N1pdm09. Viral RNA was tested by Fast set
H1N1v (Arrowdiagnostics, Italy) using ABI Prism 7300
Fast Real Time PCR System (Applied Biosystems, Italy).
This test is constituted combining a two-step reverse
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transcription-multiplex PCR with typing and sub-typing
on the electronic microarray. This assay distinguishes in-
fluenza virus types A and B, and identifies common in-
fluenza virus A subtypes H1N1 and H3N2, as well as the
potentially pandemic avian influenza virus subtype
H5N1.
The H1N1 positive samples were tested for OST-r var-
iants by one step RT-PCR amplification using single nu-
cleotide polymorphism (SNP) and directly sequenced by
cycle sequencing. This one step RT-PCR amplification
was made in house following S. Wong’s protocol [23].
Amplification was carried out using SuperScript TM
One-Step Quantitative Kit (Invitrogen) in a final volume
of 25 μl, with 5 μl of extracted RNA as template, 800
nM each of the forward and reverse primers and 200
nM of each probe. The amplification conditions were: re-
verse transcription at 48°C for 30 min, Taq activation for
10 min at 95°C, followed by 45 cycles of amplification
comprising denaturation for 15 sec at 95°C, annealing and
primer extension for 1 min at 60°C.
Sequencing of NA gene
The 2009 influenza A(H1N1) NA gene was amplified
directly from clinical specimen using the Superscript III
One-step RT-PCR amplification kit (Invitrogen, Carlsbad,
USA).
After RNA extraction, a 415 bp fragment of the NA
gene was amplified using the following primers: forward
AACACAAGAGTCTGAATGTGC, reverse ACCGTTT
CTTGAACTAATGCTT [23]. The PCR products were
further purified using QIAquickW Kit (Qiagen, Italy) and
sequenced using Big DyeW Terminator v3.1 Cycle Se-
quencing Kit (Applied Biosystem, Italy) with an ABI
PRISM 310 Genetic Analyzer. Manual examination of
the electropherogram was also performed for the iden-
tification of mixed bases, following in-house proto-
cols for diagnosis confirmation (protocols available upon
request).
Results
During the period January 1st to March 31st 2011, in the
Hematology ward of Spedali Civili of Brescia (Italy), 23
patients out of 76 (30.2%) developed nosocomial
H1N1pdm09 from the likely index case. A total of 134
specimens were performed: 41 samples resulted positive
for H1N1pdm09, and subsequently were tested for
oseltamivir resistance and 3 samples were positive.
Nosocomial acquisition was defined as the development
of symptoms attributable to pandemic influenza A that
was not present at admission in the hospital but set
within 48 hours. Most patients exhibited fever (92%) and
cough (90%); dyspnoea, sore throat and rhinorrhea were
reported in 45% of the patients. Three cases of OST-r
variant were identified during the peak activity of
H1N1pdm09 infection and in the same period three pa-
tients who required transfer to the intensive care (ICU)
because of their critical respiratory status died for fatal
influenza virus pneumonia (13.1%, patients 3, 5 and 6).
The clinical characteristics and timeline of the out-
break of H1N1pdm09 in these patients are shown in
Table 1 and Figure 1, respectively. The mean age of case
patients was 53 (range, 43-65 years) (Table 1). During
the seasonal influenza peak all these patients were ad-
mitted for reasons unrelated to influenza infection. All
patients showed ILI symptoms such as fever, cough, dys-
pnoea and sore throat, from January 26th to February
14th (Figure 1).
The presumed index case (patient1) was admitted to
the hospital on January 16th for scheduled induction
chemotherapy. She was the first case to exhibit symp-
toms of influenza. Oseltamivir administration was initi-
ated after H1N1pdm09 detection by RT- PCR and lasted
for five days (75 mg twice per day). No other viral and
bacterial respiratory pathogens were detected, and blood
cultures remained negative. At the same time, the
screening for all patients started. Four underlying malig-
nancies patients (patient 2, 3, 4 and 5) developed
hospital-acquired influenza A virus infection (Table 1)
and were present at the same time as the index patient
at the Hematology ward, without isolation procedures
(Figure 1). Patient 4 developed mild influenza symptoms
with rapid viral clearance, patient 2 developed pneumo-
nia but with resolution, whereas patients 3 and 5 de-
veloped pulmonary consolidations and fatal influenza
pneumonia.
Patients 6 was an ambulatory patient of the Hematology
ward, present in the unit at the same time of outbreak for
routine analysis. He developed pulmonary consolidation
and fatal respiratory failure. The influenza vaccination sta-
tus of these patients is not known.
All subjects were ambulatory patients, and periodically
left the ward and interacted with staff, visitors and other
inpatients while outside of their rooms. All patients
resulted positive to H1N1pdm09 virus and were admi-
nistered oseltamivir therapy: 75 mg twice/ day, for
five days.
Patients 2, 3, 5, 6 were administered oseltamivir ther-
apy several times and OST-r H1N1pdm09 with NA gene
H275Y mutation, as detected by RT PCR and confirmed
by Sanger sequencing method, emerged in patients 2, 4
and 5 (3/23, 13.1%). Mixtures of wild-type and mutant
variant (H275 H/Y) were detected only in the respiratory
specimens from patient 4. Three patients had notable
co-pathogens identified. Patients 3 and 6 had concurrent
herpesviridae (cytomegalovirus and EBV) detected by
RT-PCR in respiratory specimens and blood. Patients 4
had Stafilococcus epidermidis bacteraemia from an un-
related source.
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Three patients (3, 5, and 6) were admitted to medical
ICU, they had radiologically confirmed pneumonia with
unilateral/bilateral opacities. Findings on chest radio-
graphs were consistent with an acute respiratory distress
syndrome that required intubation and mechanical
ventilation. They died of fatal influenza pneumonia. Re-
markably, only one of the three (patient 5) was infected
by OST-r H1N1pdm09 variant. Death cause for fatal
influenza pneumonia was supported by detection of
H1N1pdm09 from post-mortem pulmonary tissue.
Table 1 Clinical Characteristic of six patients with/or without Oseltamivir resistant influenza A (H1N1) virus infection
Patient 1 Index
case
Patient 2 Patient 3 Ψ Patient 4 Patient 5 Ψ Patient 6 Ψ
Sex Female Male Male Male Male Male
Age 76 50 39 42 65 24
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Figure 1 Timeline of influenza A (H1N1) nosocomial during seasonal outbreak: all 6 patients were admitted to the haematology ward.
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Among the remaining 17 infected inpatients, 12 patients
developed influenza lower respiratory tract infection
with different levels of respiratory failure, despite the
oseltamivir therapy (diagnosis of H1N1pdm09 was con-
firmed by NAT of bronchial washings).
Moreover, it is interesting to note that, in this cluster
of patients, viral shedding persisted for a very long
period (median: 12 days, range: 7-25), longer than the
time of therapy which was administered according to
guideline (5 days).
Discussion
We report a case series of hospitalized hematologic/on-
cologic patients with H1N1pdm09 infection during the
seasonal influenza period 2010-2011 in the Hematology
ward at Spedali Civili of Brescia. In this period the
Hematology division was crowded with patients and
when the first case of H1N1pdm09 was identified, the
nosocomial influenza virus outbreak spread. Unfortu-
nately, isolation of the first infected patients was not
possible.
76 patients developed ILI, but only 23 (30.2%) were
infected of H1N1pdm09. Following a confirmed close
contact, with index patient, the other patients (53), were
infected by other respiratory viruses and bacterial patho-
gens, which were detected by routine diagnostic proce-
dures by RT-PCR. We are unable to establish whether
the health care workers or visitors contributed to viral
transmission among the patients, but during that time of
year the circulation of H1N1pdm09 was significantly
high in the community (93% of Influenza A-positive
cases were due to H1N1pdm09) and in our hospital the
total H1N1pdm09 infected patients were 57 (15%) out of
379 ILI patients. A rate of 91% of nosocomial patients
with Influenza A virus illness was H1N1pdm09 infected
and 9% was infected by influenza A (H3N2) or
unsubtypable influenza A and influenza B.
The 57 H1N1pdm09 infected patients were subjected
to drug-resistance test analysis and five resulted OST-r.
These outcomes are similar to the results obtained from
other Italian authors [15-17].
Many factors have added up to nosocomial spread of in-
fluenza: temporal overlap of inpatient stay within the
ward, prolonged viral shedding and presence of health
care workers and family members with influenza-like ill-
ness. Patients with hematologic malignancies accounted
for 50% of deaths among the patients with H1N1pdm09
infection in our Hospital (six patients died: 3 in
Hematology ward, 2 in Infectious Diseases division, 1 in
Pneumology unit). The mortality rate of RT-PCR
confirmmed H1N1pdm09 infected patients in our Hos-
pital was to 10.5%, while in Hematology ward it was
13.1%. These patients were admitted to the intensive care
unit due to development of severe respiratory failure.
In addition, our investigation confirmed that a cluster
of oseltamivir resistant H1N1pdm09 infection occurred
among 3 immuno-compromised patients in the
Hematology ward after therapy with oseltamivir. One of
them died in ICU and developed OST-r after several
weeks of therapy. No evidence was found that health
care personnel or other inpatient contacts developed ILI
caused by OST-r H1N1pdm09 variant. Resistance to
oseltamivir in H1N1pdm09 has been linked to H275Y
mutation in NA glycoprotein gene [25-27] and OST-r
H1N1pdm09 variant has been described in June 2009
among immuno-compromised patients treated with
oseltamivir [2,4,18,28] and OST-r H1N1 2009 virus was
first reported in September 2009 [2,28,29] and among fit
people who received oseltamivir therapy. Oseltamivir re-
sistance has been detected in less than 1% of untreated
patients in the community, and transmission has been
documented only in closed settings or settings involving
close contact with infected people [22,30]. Moreover, the
prevalence of OST-r viruses in the H1N1pdm09 was
very low because they are characterized by lower viru-
lence than that of wild-type viruses [31,32], and most
fatal cases of OST-r virus infection have occurred in pa-
tients with severe immune-suppression associated with
hematologic disorders [33,34] or individual risk factors
as obesity or diabetes [15,17]. However, current wide-
spread circulation of OST-r pandemic influenza A
(H1N1) 2009 virus associated with typical influenza ill-
nesses and viral pneumonia suggest that these viruses
retain significant transmissibility and pathogenicity
[33-36].
Our analysis of a critical cluster of patients with
H1N1pdm09 infection reveals that this disease affected
middle age patients, most of them with underlying
chronical diseases. Indeed, we observed that patient 5
who became infected by drug resistant virus after
prolonged therapy, developed pneumonia, rapidly
progressing and leading to death. Other investigators
reported similar results: usually, resistance in these pa-
tients emerges in response to antiviral drug selection
pressure [4,16,18,20-22].
We found a relatively high incidence of drug resistant
viruses, i.e. 3 out of 23 H1N1pdm09 infected patients, as
confirmed by RT-PCR, after several cycles of oseltamivir
therapy. This also appeared to affect the severity of the
disease, as these three positive patients were critically ill.
The OST-r in hematologic/oncological patients suggests
that immuno-suppressed patients have increased risk for
complications of influenza and of developing resistant
strains [33,34,36]. Early identification and prolonged iso-
lation precautions appear necessary in taking care of
infected immuno-compromised patients like critical
hematologic/oncological patients. For prevention and
control of seasonal influenza among these patients,
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influenza vaccination is recommended, (as well as in
their family members and health care workers), although
the immune response to vaccination can be low in these
patients [31,32,35].
Conclusions
Our study has limitations since it is a retrospective, single
center observational study, with a relatively small set of
data analyzed. The pathogenetic role of OST-r variants
observed remains to be confirmed in a larger cohort.
Nevertheless, our results underscore the need for diag-
nostic vigilance and early isolation to prevent nosocomial
transmission of influenza and other seasonal influenza
infections among immuno-compromised patients. More-
over, influenza virus and other respiratory viruses should
always be considered in the differential diagnosis of fever
or respiratory symptoms in hospitalized patients when the
prevalence of such respiratory viral infections is high in
the community.
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